Patents by Inventor Gilles Flatau

Gilles Flatau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR
    Publication number: 20100266632
    Abstract: An immunogenic or vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase activator. The Activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine.
    Type: Application
    Filed: November 30, 2009
    Publication date: October 21, 2010
    Inventors: Emmanuel Lemichez, Cecil Czerkinsky, Fabienne Anjuere, Patrice Boquet, Patrick Munro, Gilles Flatau
  • Vaccine composition comprising an immunoadjuvant compound consisting of a Rho GTPase family activator
    Patent number: 7655240
    Abstract: This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a Rho GTPase activator.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: February 2, 2010
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Emmanuel Lemichez, Cécil Czerkinsky, Fabienne Anjuere, Patrice Boquet, Patrick Munro, Gilles Flatau
  • Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator
    Publication number: 20070172491
    Abstract: This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a Rho GTPase activator.
    Type: Application
    Filed: February 25, 2005
    Publication date: July 26, 2007
    Inventors: Emmanuel Lemichez, Cecil Czerkinsky, Fabienne Anjuere, Patrice Boquet, Patrick Munro, Gilles Flatau